These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

73 related articles for article (PubMed ID: 23532333)

  • 1. BIM, PUMA, and the achilles' heel of oncogene addiction.
    Roulston A; Muller WJ; Shore GC
    Sci Signal; 2013 Mar; 6(268):pe12. PubMed ID: 23532333
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A novel BIM deletion polymorphism: implications and lessons for cancer targeted therapies.
    Soh S; Ong ST
    Rinsho Ketsueki; 2013 Oct; 54(10):1714-9. PubMed ID: 24064821
    [No Abstract]   [Full Text] [Related]  

  • 3. Oncogene addiction: pathways of therapeutic response, resistance, and road maps toward a cure.
    Pagliarini R; Shao W; Sellers WR
    EMBO Rep; 2015 Mar; 16(3):280-96. PubMed ID: 25680965
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The pan-Bcl-2 blocker obatoclax promotes the expression of Puma, Noxa, and Bim mRNA and induces apoptosis in neoplastic mast cells.
    Peter B; Cerny-Reiterer S; Hadzijusufovic E; Schuch K; Stefanzl G; Eisenwort G; Gleixner KV; Hoermann G; Mayerhofer M; Kundi M; Baumgartner S; Sperr WR; Pickl WF; Willmann M; Valent P
    J Leukoc Biol; 2014 Jan; 95(1):95-104. PubMed ID: 24052572
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Heritable resistance to tyrosine kinase inhibitors.
    Ong ST
    Clin Adv Hematol Oncol; 2014 Jul; 12(7):454-7. PubMed ID: 25322326
    [No Abstract]   [Full Text] [Related]  

  • 6. Thiazolide-induced apoptosis in colorectal cancer cells is mediated via the Jun kinase-Bim axis and reveals glutathione-S-transferase P1 as Achilles' heel.
    Sidler D; Brockmann A; Mueller J; Nachbur U; Corazza N; Renzulli P; Hemphill A; Brunner T
    Oncogene; 2012 Sep; 31(37):4095-106. PubMed ID: 22158036
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Apoptosis and autophagy: BIM as a mediator of tumour cell death in response to oncogene-targeted therapeutics.
    Gillings AS; Balmanno K; Wiggins CM; Johnson M; Cook SJ
    FEBS J; 2009 Nov; 276(21):6050-62. PubMed ID: 19788418
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Proapoptotic BH3-only BCL-2 family protein BIM connects death signaling from epidermal growth factor receptor inhibition to the mitochondrion.
    Deng J; Shimamura T; Perera S; Carlson NE; Cai D; Shapiro GI; Wong KK; Letai A
    Cancer Res; 2007 Dec; 67(24):11867-75. PubMed ID: 18089817
    [TBL] [Abstract][Full Text] [Related]  

  • 9. EGFR-TKI resistance due to BIM polymorphism can be circumvented in combination with HDAC inhibition.
    Nakagawa T; Takeuchi S; Yamada T; Ebi H; Sano T; Nanjo S; Ishikawa D; Sato M; Hasegawa Y; Sekido Y; Yano S
    Cancer Res; 2013 Apr; 73(8):2428-34. PubMed ID: 23382048
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The NF-kappaB regulator Bcl-3 and the BH3-only proteins Bim and Puma control the death of activated T cells.
    Bauer A; Villunger A; Labi V; Fischer SF; Strasser A; Wagner H; Schmid RM; Häcker G
    Proc Natl Acad Sci U S A; 2006 Jul; 103(29):10979-84. PubMed ID: 16832056
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of B-RAF mutant human tumor cells with a MEK inhibitor requires Bim and is enhanced by a BH3 mimetic.
    Cragg MS; Jansen ES; Cook M; Harris C; Strasser A; Scott CL
    J Clin Invest; 2008 Nov; 118(11):3651-9. PubMed ID: 18949058
    [TBL] [Abstract][Full Text] [Related]  

  • 12. FKHRL1-mediated expression of Noxa and Bim induces apoptosis via the mitochondria in neuroblastoma cells.
    Obexer P; Geiger K; Ambros PF; Meister B; Ausserlechner MJ
    Cell Death Differ; 2007 Mar; 14(3):534-47. PubMed ID: 16888645
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Functional and biological analysis of Bcl-xL expression in human osteosarcoma.
    Wang ZX; Yang JS; Pan X; Wang JR; Li J; Yin YM; De W
    Bone; 2010 Aug; 47(2):445-54. PubMed ID: 20580954
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bim and Bad mediate imatinib-induced killing of Bcr/Abl+ leukemic cells, and resistance due to their loss is overcome by a BH3 mimetic.
    Kuroda J; Puthalakath H; Cragg MS; Kelly PN; Bouillet P; Huang DC; Kimura S; Ottmann OG; Druker BJ; Villunger A; Roberts AW; Strasser A
    Proc Natl Acad Sci U S A; 2006 Oct; 103(40):14907-12. PubMed ID: 16997913
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Puma cooperates with Bim, the rate-limiting BH3-only protein in cell death during lymphocyte development, in apoptosis induction.
    Erlacher M; Labi V; Manzl C; Böck G; Tzankov A; Häcker G; Michalak E; Strasser A; Villunger A
    J Exp Med; 2006 Dec; 203(13):2939-51. PubMed ID: 17178918
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Epigenetic down-regulation of BIM expression is associated with reduced optimal responses to imatinib treatment in chronic myeloid leukaemia.
    San José-Eneriz E; Agirre X; Jiménez-Velasco A; Cordeu L; Martín V; Arqueros V; Gárate L; Fresquet V; Cervantes F; Martínez-Climent JA; Heiniger A; Torres A; Prósper F; Roman-Gomez J
    Eur J Cancer; 2009 Jul; 45(10):1877-89. PubMed ID: 19403302
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PI3K/mTOR dual inhibitor NVP-BEZ235 decreases Mcl-1 expression and sensitizes ovarian carcinoma cells to Bcl-xL-targeting strategies, provided that Bim expression is induced.
    Jebahi A; Villedieu M; Pétigny-Lechartier C; Brotin E; Louis MH; Abeilard E; Giffard F; Guercio M; Briand M; Gauduchon P; Lheureux S; Poulain L
    Cancer Lett; 2014 Jun; 348(1-2):38-49. PubMed ID: 24650799
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A critical role for TNF receptor-associated factor 1 and Bim down-regulation in CD8 memory T cell survival.
    Sabbagh L; Srokowski CC; Pulle G; Snell LM; Sedgmen BJ; Liu Y; Tsitsikov EN; Watts TH
    Proc Natl Acad Sci U S A; 2006 Dec; 103(49):18703-8. PubMed ID: 17116875
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MiR-25 regulates apoptosis by targeting Bim in human ovarian cancer.
    Zhang H; Zuo Z; Lu X; Wang L; Wang H; Zhu Z
    Oncol Rep; 2012 Feb; 27(2):594-8. PubMed ID: 22076535
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Bim deletion polymorphism clinical profile and its relation with tyrosine kinase inhibitor resistance in Chinese patients with non-small cell lung cancer.
    Zhao M; Zhang Y; Cai W; Li J; Zhou F; Cheng N; Ren R; Zhao C; Li X; Ren S; Zhou C; Hirsch FR
    Cancer; 2014 Aug; 120(15):2299-307. PubMed ID: 24737648
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.